G04CB02 - Dutasteride |
Propably not porphyrinogenic |
PNP |
Rationale
Dutasteride is not a substrate, inhibitor or inducer of CYP450 enzymes and no pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Oxosteroide
Therapeutic characteristics
Dutasteride is a testosterone 5-alpha-reductase inhibitor used in the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).
It is administered orally.
Metabolism and pharmakokinetics
Dutasteride is metabolized by CYP3A4/5 (SPC). Dutasteride and its metabolites are mainly excreted in the feaces (SPC).
Dutasteride does not have an effect on warfarin or digoxin and is thus not an inhibitor or inducer of CYP2C9 (SPC). In vitro interaction studies report that it is not an inhibitor of CYP1A2, 2A6, 2E1, 2C8, 2D6, 2C9, 2C19, 2B6 or 3A4 (SPC). No drug-drug interactions with dutasteride as perpetrator have been reported in the literature (Lexi-Interact, Keam 2008).
References
- Scientific articles
- Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. PMID 18318566. #1576
- Government bodies
- #1302
- Drug interaction databases
- Lexi-Interact in UpToDate. Dutasteride: Drug interaction program. #1575
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Avodart). #1577
Similar drugs
© NAPOS 2024